Statin therapy in metabolic syndrome and hypertension post-JUPITER: what is the value of CRP?

Authors:
Devaraj S; Siegel D; Jialal I.

Journal:
Curr Atheroscler Rep

Publication Year: 2011

DOI:
10.1007/s11883-010-0143-2

PMCID:
PMC3018293

PMID:
21046291

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Curr Atheroscler Rep

Abbreviation: Curr Atheroscler Rep

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Vascular Diseases

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
How Will Our Practice Change After the CLEAR Outcomes Trial?
Abrahams T; Nelson AJ; Nicholls SJ. (2024) - Transparency Score: 3/6
Lipoprotein(a): from Causality to Treatment.
Kronenberg F. (2024) - Transparency Score: 3/6
Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon?
Surma S; Sahebkar A; Banach M. (2024) - Transparency Score: 2/6
Apheresis: What Should a Clinician Know?
Parhofer KG. (2023) - Transparency Score: 3/6
APOC-III: a Gatekeeper in Controlling Triglyceride Metabolism.
Giammanco A; Spina R; Cefalù AB and 1 more (2023) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
2/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Disclosure Sridevi Devaraj reports no potential conflict of interest relevant to this article. David Siegel reports no potential conflict of interest relevant to this article. Ishwarlal Jialal reports no potential conflict of interest relevant to this article."

Evidence found in paper:

"Grant Support: NIH K24AT00596, NIH RO1HL74360"

Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025